



South Central Section of the AUA, Inc.

**VIRTUAL**  
**99TH ANNUAL MEETING**  
**OCTOBER 10, 2020**

**EXHIBIT GUIDE**

# Special Thanks to Our Industry Supporters

Without the support of our industry partners we would not be able to hold our annual meeting.  
We would like to acknowledge them and thank them for their continued support.

## Promotional Partners

### Platinum Level



### Gold Level



### Silver Level





# Xtandi<sup>®</sup>


(enzalutamide)  
40 mg capsules

To learn more, visit  
**XtandiHCP.com**



© 2020 Astellas Pharma US, Inc. and Pfizer Inc. All rights reserved. 076-5905-PM 9/20  
XTANDI, Astellas, and the flying star logo are registered trademarks of Astellas Pharma Inc.

**Lynparza**<sup>®</sup>  
olaparib   
tablets 150 mg

A man with short dark hair, wearing a light-colored button-down shirt over a grey t-shirt, stands in a workshop. In the background, there is a yellow car on a lift and various mechanical equipment.

**HAVE YOU EXPLORED  
THE CLINICAL AND SAFETY  
DATA FOR CERTAIN USES?**

***Discover more at [LynparzaPrcHCP.com](https://lynparzaPrcHCP.com)***



LYNPARZA is a registered trademark of the AstraZeneca group of companies.  
©2020 AstraZeneca. All rights reserved. US-45594 Last Updated 9/20

# *Special Thanks to Our Industry Supporters*

## **Thank You to Our 2020 Sponsors**

American Urological Association

Astellas Pharma and Pfizer Oncology

Astellas Pharma US, Inc.

AstraZeneca

Bayer HealthCare

Blue Earth Diagnostics, Inc.

CAREstream America

Clarus Therapeutics, Inc.

Coloplast

Cook Medical

Endo Pharmaceuticals

Exact Sciences

Janssen Biotech, Inc.

Lumenis, Inc.

Medtronic

Myriad Genetics, Inc.

NeoTract Teleflex

PathRight Medical

Retrophin

TOLMAR Pharmaceuticals

UroGen Pharma, Inc.



# WHEN IS IT TIME TO INTRODUCE XOFIGO® ?


CLICK HERE TO LEARN MORE



This information has been reviewed according to US law, is consistent with US Prescribing Information, and is intended for HCPs only. Prescribing Information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the Prescribing Information and/or the Summary of Product Characteristics (SmPC).



Myriad offers a suite of genetic testing products to help answer your patient's most pressing questions while allowing you to better understand their individual cancer risk



Are additional therapies available?

How aggressive should initial treatment be?

Is Active Surveillance safe for me?

	LOW RISK	FAVORABLE INTERMEDIATE RISK	UNFAVORABLE INTERMEDIATE RISK	HIGH RISK	METASTATIC
TUMOR AGGRESSION	MYRIAD Prolaris <sup>®</sup> Prostate Cancer	MYRIAD Prolaris <sup>®</sup> Prostate Cancer	MYRIAD Prolaris <sup>®</sup> Prostate Cancer	MYRIAD Prolaris <sup>®</sup> Prostate Cancer	
GERMLINE MUTATIONS	BRACAnalysisCDx <sup>®</sup>	BRACAnalysisCDx <sup>®</sup> MYRIAD myRisk <sup>®</sup> Hereditary Cancer	BRACAnalysisCDx <sup>®</sup> MYRIAD myRisk <sup>®</sup> Hereditary Cancer	BRACAnalysisCDx <sup>®</sup> MYRIAD myRisk <sup>®</sup> Hereditary Cancer	BRACAnalysisCDx <sup>®</sup> MYRIAD myRisk <sup>®</sup> Hereditary Cancer

# Scientific Program

Please note, all times are listed in Central Time

## Saturday, October 10, 2020

8:00 a.m. - 9:00 a.m.	<b>Industry Sponsored Symposium:</b> <b>Treatment of mCRPC with LYNPARZA: A New Oral Therapy Approved for Patients with HRR Gene Mutations Following Progression on Enzalutamide or Abiraterone</b> Speaker: Lawrence I. Karsh, MD, FACS <b>Sponsored by AstraZeneca</b>
9:00 a.m. - 9:05 a.m.	<b>Introduction and Welcome</b> President: James M. Cummings, MD, FACS Program Chair: Michael S. Cookson, MD, MMHC, FACS
9:05 a.m. - 9:50 a.m.	<b>Controversies in Men's Health: A Case Based Approach</b> Moderator: Mohit Khera, MD, MBA, MPH Panelists: Ty T. Higuchi, MD, PhD Parviz K. Kavoussi, MD, FACS Saneal Rajanahally, MD
9:50 a.m. - 10:30 a.m.	<b>AUA Course of Choice Lecture: Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease &amp; CRPC</b> Guest Speaker: Todd M. Morgan, MD
10:30 a.m. - 11:15 a.m.	<b>Panel Discussion: High Risk Clinically Localized Prostate Cancer</b> Moderator: John W. Davis, MD, FACS Panelists: Janet B. Kukreja, MD, MPH Brian J. Miles, MD Todd M. Morgan, MD William P. Parker, MD
11:15 a.m. - 12:00 p.m.	<b>Controversies in Reconstructive Urology</b> Moderator: Allen F. Morey, MD Panelists: James R. Furr, MD Alexander T. Rozanski, MD Shyam Sukumar, MD

# Scientific Program


12:00 p.m. - 1:00 p.m.	<b>Industry Sponsored Symposium:</b> <b>Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape</b> Speaker: Scott Sellinger, MD, FACS <i>Sponsored by Astellas Pharma and Pfizer Oncology</i>
1:00 p.m. - 1:35 p.m.	<b>Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA/SUFU Guideline(2019)</b> Guest Speaker: Ekene A. Enemchukwu, MD, MPH
1:35 p.m. - 2:10 p.m.	<b>Difficult Cases of Male Stress Incontinence: Surgical Considerations</b> Moderator: Brian J. Flynn, MD Panelists: Erin T. Bird, MD, MBA Joshua A. Broghammer, MD, FACS Gennady Slobodov, MD O. Lenaine Westney, MD
2:10 p.m. - 2:50 p.m.	<b>Telehealth and Lessons Learned from COVID-19 Pandemic</b> Moderators: Tomas L. Griebing, MD, MPH Julie M. Riley, MD, FACS Panelists: Stephen J. Canon, MD Phillip Fuller, MD Neema Navai, MD
2:50 p.m. - 3:30 p.m.	<b>Panel Discussion: Small Renal Masses: Beyond the Guidelines</b> Moderator: J. Stuart Wolf, Jr., MD, FACS Panelists: Simon Kim, MD, MPH Moben Mirza, MD, FACS Sanjay Patel, MD Deepak K. Pruthi, MD, MSCI-TS, FRCSC
3:30 p.m. - 4:00 p.m.	<b>Presidential Address: Urology and the Presidency</b> President: James M. Cummings, MD, FACS
4:00 p.m. - 5:00 p.m.	<b>Annual Business Meeting*</b> <i>*Open to SCS members only</i>

FOR **EARLY-** AND **LATE-STAGE** PROSTATE CANCER

## Navigate your prostate cancer patient's journey with Oncotype DX® tests

oncotype DX®  
Genomic Prostate Score

FOR YOUR  
**EARLY-STAGE**  
PATIENTS



oncotype DX®  
AR-V7 Nucleus Detect  
powered by Epic Sciences

FOR YOUR  
**LATE-STAGE**  
PATIENTS

Scan the code  
to learn more



mCRPC = metastatic castration-resistant prostate cancer.  
†Androgen receptor (AR)-targeted therapies include Erleada™ (apalutamide), Zytiga® (abiraterone), and Xtandi® (enzalutamide).  
Oncotype DX, Oncotype DX Genomic Prostate Score, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect, and AR-V7 Nucleus Detect are trademarks of Genomic Health Inc., an Exact Sciences corporation. Exact Sciences is a registered trademark of Exact Sciences corporation.  
©2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. GHI60068\_0220

**EXACT**  
**SCIENCES**

The image depicted contains models and is being used for illustrative purposes only. Janssen Global Services, LLC. © JCS2019

# Cancer breakthroughs take time. That's why we work at such a furious pace.

To stop the growth of cancer, we are developing treatments that work with the body's natural defenses. Focusing on immunotherapy gets us closer to a future where disease is a thing of the past.

© Janssen Biotech, Inc. 08/20 cp-172797v1

janssen  Oncology

PHARMACEUTICAL COMPANIES OF 



# He stays current. So does his LHRH therapy.



To learn more, visit us at  
**EligardHCP.com**

## Current science reflects testosterone target levels of $\leq 20$ ng/dL.<sup>1</sup>

LEARN MORE

Achieving and maintaining **low testosterone (T) to surgical castration level** is the goal of androgen deprivation therapy (ADT) for advanced prostate cancer.

*"Increasing evidence suggests that the historical target threshold for serum testosterone concentration when using ADT in treating advanced prostate cancer ( $\leq 50$  ng/dL) is not equivalent to the concentrations achieved by surgical castration."*

— Shore et al., 2016<sup>1</sup>

### IMPORTANT SAFETY INFORMATION

ELIGARD is indicated for the palliative treatment of advanced prostate cancer. ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage

according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. **Click for full Prescribing and Safety Information.**

**Reference:** 1. Shore N, et al., *BJU Int.* 2016

© 2020 Tolmar Pharmaceuticals, Inc. All rights reserved. Tolmar and ELIGARD and their associated logos are a trademarks of the Tolmar group. TPI.2020.2473.v1 09/20

  
[www.tolmar.com](http://www.tolmar.com)

# Special Thanks to Our Industry Supporters



American  
Urological  
Association

## American Urological Association

With more than 23,000 members worldwide, the American Urological Association (AUA) is the premier urologic association, providing invaluable support to the urologic community through education, research and the formulation of health policy. The Urology Care Foundation, the official foundation of the AUA, is a dedicated leader in advancing urologic research and education throughout the world to improve patients' lives.

For more information, please visit:

<http://auanet.org/membership/member-benefits-and-programs>



## Astellas Pharma US

Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

For more information, please visit: [www.astellas.com/us](http://www.astellas.com/us)

## Pfizer Oncology

At Pfizer, we strive to bring innovative treatments to the forefront by developing therapies that provide maximum efficacy while minimizing adverse effects for the patient.

Our current portfolio of oncology therapies covers a range of cancers. We continue to study these therapies alone and in combination with other treatments to fully explore their ability to improve the lives of cancer patients.

For more information; please visit: [www.pfizer.com/science/oncology-cancer](http://www.pfizer.com/science/oncology-cancer)



## Astellas Pharma US

Astellas Pharma US, Inc is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. With a steadfast focus on addressing unmet medical needs and conducting our business with ethics and integrity, we strive to improve the health of people throughout the Americas and around the world.

For more information on Astellas, please go to [www.astellas.com/us](http://www.astellas.com/us).

# *Special Thanks to Our Industry Supporters*



## **AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

For more information, please visit [www.astrazeneca-us.com](http://www.astrazeneca-us.com) and follow us on Twitter @AstraZenecaUS.



## **BAYER HEALTHCARE- ONCOLOGY**

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.

For more information; please visit: [WWW.BAYER.US.COM](http://WWW.BAYER.US.COM)



## **Blue Earth Diagnostics, Inc.**

Blue Earth Diagnostics is an established molecular imaging company focused on providing innovative, well-differentiated diagnostics solutions, informing patient management, and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics' success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue Earth Diagnostics' clinical focus is exclusively in cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.

For more information; please visit: [www.blueearthdiagnostics.com](http://www.blueearthdiagnostics.com)



## **CAREstream America**

CAREstream America provides innovative therapy and product solutions for premium urologic care. Our comprehensive portfolio includes Pro-Nox™, a 50/50 Nitrous Oxide and Oxygen gas delivery system for safe and effective relief of procedure pain and anxiety. Additionally, we offer PRFM autologous therapy, Radialspec Acoustic Wave, and VeinViewer to illuminate patient veins in HD.

View our suite of solutions by visiting [www.carestreamamerica.com](http://www.carestreamamerica.com) and connect with us to schedule a private or virtual demo.

# *Special Thanks to Our Industry Supporters*



## **Clarus Therapeutics, Inc.**

The Clarus Therapeutics team is singularly focused on men's health. At our core, we're dedicated to advancing care for a specific type of hypogonadal man—those who have low to no testosterone due to certain medical conditions. We've made it our mission to empower men with our commitment to their health and well-being.

For more information; please visit: [www.clarustherapeutics.com](http://www.clarustherapeutics.com)



## **Coloplast**

Making life easier for people with intimate healthcare needs, Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological conditions to include stress urinary incontinence, pelvic organ prolapse, Peyronie's disease, kidney stones and ED. Products include the new Titan® Touch, Restorelle®, Altis®, and ReTrace®.

For more information; please visit: [www.coloplastmd.com](http://www.coloplastmd.com)



## **Cook Medical**

A patient-first philosophy and innovative spirit have helped Cook become a leader in urology. With a focus on stone management and biopsy, we pride ourselves on providing quality solutions without compromise. By uniting with healthcare professionals around the world, we're committed to advancing treatment and making a difference, together.

For more information; please visit: [www.cookmedical.com/quanta](http://www.cookmedical.com/quanta)



## **Endo Pharmaceuticals**

Endo Pharmaceuticals Inc., headquartered in Malvern, PA, develops and markets high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals' specialty portfolio includes products for urology, men's health, orthopedics and endocrinology. Endo Pharmaceuticals is an Endo company (NASDAQ: ENDP), a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.

Learn more at [www.endo.com](http://www.endo.com), [www.endopharma.com](http://www.endopharma.com), or [peyronies-disease.xiaflex.com/patient/](http://peyronies-disease.xiaflex.com/patient/)

# Special Thanks to Our Industry Supporters



## Exact Sciences / Oncotype DX

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.

For more information, please visit the company's website at [www.exactsciences.com](http://www.exactsciences.com), [www.oncotypeiq.com/en-US](http://www.oncotypeiq.com/en-US), follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.



## Janssen Biotech, Inc.

At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts.

For more information, visit [www.janssen.com](http://www.janssen.com) or [www.erleadahcp.com](http://www.erleadahcp.com)



## Lumenis

Better Technology for Better Patient Care

Lumenis is the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

For more information; please visit: [lumenis.com](http://lumenis.com)



## Medtronic

The Medtronic Mission is to contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health, and extend life.

Medtronic Pelvic Health is the world leader in Sacral Neuromodulation Therapy for bowel and bladder control.

For more information; please visit: [www.medtronic.com/bladder](http://www.medtronic.com/bladder)

# Special Thanks to Our Industry Supporters



## Myriad Genetics

Myriad Genetics is a leading personalized medicine company dedicated to being a trusted advisor and transforming patient lives worldwide with molecular diagnostics. Myriad discovers and commercializes diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

For more information on how Myriad is making a difference, please visit the Company's website: [www.myriad.com](http://www.myriad.com).



## NeoTract Teleflex

The UroLift System procedure is a minimally invasive approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue. It is an earlier treatment alternative for more BPH patients. The Prostatic Urethral Lift (UroLift System) is recommended by the AUA Guidelines for the treatment of men with BPH. Now having treated over 200,000 patients.

Visit our website at [www.urolift.com](http://www.urolift.com).



## PathRight Medical

PathRight Medical manufactures the RestoreX® device, a next generation penile traction therapy device for the treatment of Peyronie's disease. RestoreX reduces curvature and restores lost length in just 60-minutes of treatment per day for 12 weeks. Preliminary data also suggests RestoreX reduces the occurrence of lost penile length due to post-prostatectomy or restores lost penile length resulting from chronic disease.

For more information; please visit: [www.restorex.com](http://www.restorex.com)



## Retrophin- Thiola EC

THIOLA EC® (tiopronin, delayed-release tablets) is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.

Learn more about THIOLA EC and contact a local representative at [www.thiolaechcp.com](http://www.thiolaechcp.com).

# *Special Thanks to Our Industry Supporters*



## **TOLMAR Pharmaceuticals**

Tolmar is committed to the development, approval, and commercialization of specialty pharmaceutical products dedicated to advancing patient care in urology.

We are focused on the needs of today, with a vision of tomorrow that drives our dedication to the urology community and the patients it serves.

For more information; please visit: [www.eligardhcp.com](http://www.eligardhcp.com)



## **UroGen Pharma, Inc.**


UroGen is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated because patients deserve better options. Our vision to pioneer new treatments is grounded in our innovative drug delivery technology platform RTGel™, our promising pipeline and a collaborative drive for bold results.

For more information; please visit: [www.jelmyto.com/hcp](http://www.jelmyto.com/hcp)

**Where will your patients go with Myrbetriq® (mirabegron)?**

**Find out at the Astellas booth.**



Subway 

 **Myrbetriq®**  
(mirabegron)  
extended-release tablets  
25 mg, 50 mg


Myrbetriq, Astellas, and the flying star logo are registered trademarks of Astellas Pharma Inc.  
©2019 Astellas Pharma US, Inc.

All rights reserved.

Printed in USA

057-3394-PM

July 2019



**BLUE EARTH**  
D I A G N O S T I C S  
A Bracco Company

Blue Earth Diagnostics, Inc., is pleased to  
support the 2020 South Central Section of  
the AUA Annual Meeting



*I am a urologist. I am a patient.*

**"** When my BPH symptoms became unbearable I really didn't want to undergo invasive surgery and I'm not a personal fan of BPH medications. Relief can be inadequate and temporary and they have a whole host of side effects.**"**

**Peter J. Walter, M.D., F.A.C.S.®** Western New York Urology Associates and UROLIFT® SYSTEM PATIENT

Enlarged Prostate (BPH) affects over 40 million men in the United States. Symptoms may include interrupted sleep and urinary problems as well as loss of productivity, depression and decreased quality of life.<sup>2</sup>

If your patients have symptoms of an enlarged prostate, introduce them to the UroLift® System. Here's why I chose UroLift System and recommend it to my patients.

**Proven**, minimally invasive approach to treating enlarged prostate that provides rapid symptom relief and recovery<sup>3,4</sup>

**An earlier alternative** to medical therapy that provides symptom relief better than reported for medication<sup>3,5</sup>

**Durability** through 5 years<sup>6</sup>


**Over 175,000\*\*** men have been treated with the UroLift System worldwide

The procedure is **covered by Medicare** and all major private insurers when medical criteria are met.


Learn more and check out the data at [UroLift.com/info](http://UroLift.com/info)




PRE-PROCEDURE



POST-PROCEDURE



UroLift® Implant  
Actual Size



The UroLift System procedure is FDA-cleared for the treatment of symptoms due to urinary outflow obstruction secondary to BPH, including lateral and median lobe hyperplasia, in men 45 years of age or older. Results and patient experience may vary. Clinical data from a pivotal 206-patient randomized controlled study showed that most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within 2 to 4 weeks after the procedure.

\*Dr. Walter is UroLift System faculty and a paid consultant for NeoTract | Teleflex. \*\*Management estimate based on product sales and average units per procedure

1. AUA Guidelines 2003, 2010; 2. Speakman et al. 2014 BJUI International; 3. Roehrborn J Urol 2013 L.I.F.T. Study;

4. Shore, Can J Urol 2014 Local Study; 5. AUA BPH Guidelines 2003; 6. Roehrborn et al. Can J Urol 2017

©2020 NeoTract, Inc. All rights reserved. MAC00901-05 Rev B

neotrack® | Teleflex®  
INTERVENTIONAL UROLOGY

## AN INNOVATIVE TECHNOLOGY. A FIRST-OF-ITS-KIND TREATMENT.

See what sets JELMYTO apart  
at [JELMYTO.com/hcp](http://JELMYTO.com/hcp)

**Jelmyto®**  
(mitomycin) for pyelocalyceal solution





South Central Section of the AUA, Inc.  
Two Woodfield Lake  
1100 E. Woodfield Rd., Ste 350  
Schaumburg, IL 60173  
(847) 605-0850  
[info@scsauala.org](mailto:info@scsauala.org)  
[scsauala.org](http://scsauala.org)